PERSPECTA

News from every angle

← Back to headlines

Evercore ISI Maintains "Outperform" Rating on BridgeBio Pharma

Evercore ISI has retained its "Outperform" rating on BridgeBio Pharma, Inc. (BBIO), indicating a positive outlook for the pharmaceutical company's stock.

13 May, 17:53 — 13 May, 17:53
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual107d ago

Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)

Read full article →

Related Stories

Fed’s Warsh Hints at Further Rate Increases as Inflation Remains Elevated

24m ago

BYD Reports First Quarterly Profit Rise in Over a Year on Export Surge

46m ago

US-Mexico Trade Talks Stall Over Dispute on Cheese Names

1h ago

Walmart Reaches Settlement With U.S. Government Over Opioid Crisis

1h ago